Triad Wealth Partners LLC Increases Stake in IDEXX Laboratories, Inc. $IDXX

Triad Wealth Partners LLC increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 20.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 869 shares of the company’s stock after buying an additional 146 shares during the period. Triad Wealth Partners LLC’s holdings in IDEXX Laboratories were worth $466,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. J. Safra Sarasin Holding AG increased its stake in shares of IDEXX Laboratories by 74.2% during the second quarter. J. Safra Sarasin Holding AG now owns 3,610 shares of the company’s stock valued at $1,936,000 after buying an additional 1,538 shares during the period. Platinum Investment Management Ltd. purchased a new position in IDEXX Laboratories in the second quarter valued at about $1,877,000. Robeco Institutional Asset Management B.V. grew its stake in IDEXX Laboratories by 39.8% in the second quarter. Robeco Institutional Asset Management B.V. now owns 207,228 shares of the company’s stock valued at $111,145,000 after purchasing an additional 58,991 shares during the last quarter. Heritage Financial Services LLC purchased a new position in IDEXX Laboratories in the second quarter valued at about $220,000. Finally, Madrona Financial Services LLC purchased a new position in IDEXX Laboratories in the second quarter valued at about $224,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $631.19 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11. The company has a market cap of $50.50 billion, a PE ratio of 52.56, a P/E/G ratio of 4.10 and a beta of 1.58. The business has a 50-day simple moving average of $634.52 and a two-hundred day simple moving average of $534.79. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter last year, the company earned $2.44 earnings per share. The company’s quarterly revenue was up 10.6% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

Insider Activity

In related news, EVP Sharon E. Underberg sold 5,450 shares of IDEXX Laboratories stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $651.60, for a total transaction of $3,551,220.00. Following the completion of the sale, the executive vice president owned 6,156 shares of the company’s stock, valued at $4,011,249.60. The trade was a 46.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Michael G. Erickson sold 406 shares of IDEXX Laboratories stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $649.96, for a total value of $263,883.76. Following the sale, the executive vice president directly owned 11,287 shares of the company’s stock, valued at $7,336,098.52. This trade represents a 3.47% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 54,057 shares of company stock valued at $34,293,468. 0.98% of the stock is owned by insiders.

Analysts Set New Price Targets

Several equities analysts have issued reports on IDXX shares. Leerink Partners lifted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, July 17th. Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Saturday, September 27th. Morgan Stanley lifted their target price on IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a research note on Friday, August 15th. Piper Sandler reiterated a “neutral” rating and issued a $700.00 target price (up previously from $510.00) on shares of IDEXX Laboratories in a research note on Monday, August 11th. Finally, JPMorgan Chase & Co. lifted their target price on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a research note on Monday, August 4th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories has an average rating of “Moderate Buy” and an average target price of $656.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.